A few words from our Chairman
« Genomic Vision had a successful year of transition, leading to more structured and refined global approach to its activity for the year 2023.
Our strategic reorientation was made possible thanks to the replacement of our governance, the strengthening of our management team and the implementation of new national and international partnership agreements.
Since this reorganization, our work is now focused on promising new markets such as bioproduction and gene and cell therapy.
The objective is clear: to put our technological solutions at the service of quality control of medical treatment.
Sign of a future phase of growth for Genomic Vision, the structuring projects on which we are working will allow us to capitalize on a sector in the future and achieve a long lasting success. »
Chairman of the Executive Board
Standard chemotherapies are based on the use of cytotoxic compounds that will enhance the replication stress response of cancer cells to impair their multiplication.
Genomic Vision’s proprietary assay, Replication Combing Assay (RCA), is a powerful approach to evaluate the efficacy of chemotherapy compounds targeting DNA replication or repair pathways, via monitoring spatial and temporal parameters of DNA replication at a single-molecule resolution. Thousands of DNA molecules from cells treated under various conditions (e.g., different drugs, concentration, timing etc.) can be stretched at a constant rate simultaneously on treated coverslip allowing us to precisely evaluate parameters that can be affected by replicative stress or DNA damage such as DNA replication speed, fork stalling, fork restart or inter-origin distances.
Cell and Gene Therapy
The field of healthcare where delivery of genetic materials via vector/carrier system (developed for genetic alteration or cellular modification) into the patients for amelioration of disease.
With Molecular Combing technology, the positive identification, genetic integrity, on and off target insertion, stability characterization of the therapeutic product can serve as a Quality Control requirement for heathier and safer treatment.
“Adding Molecular Combing to our laboratory expertise will help us expand our research on how DNA damage, unusual DNA structures, and changes in replisome composition affect DNA replication and give rise to genome instability and increased cancer risk”.
Professor Kristina Schmidt
Professor of Cell & Molecular Biology at the University of South Florida
“We are very excited to utilize Genomic Vision’s TeloSizer® to develop highly accurate companion tests that will benefit patients. TeloSizer® offers greater accuracy and more information compared to other telomere measurement methods.”
Group leader at Centre National de la Recherche Scientifique (CNRS)
“FiberSmart® sets new standards in the analysis and quantification of Replication Combing Assays. It offers automated recognition of DNA structures, as well as ease and speed of use.”
Helmut Pospiech, Ph.D.
Senior Research Fellow at Fritz Lipmann Institute
“TeloSizer® will provide new information on individual telomere length and their distribution”.
Deputy Director of Centre de Recherche en Cancérologie de Marseille (CRCM) expert in telomeres